ACADIA Pharmaceuticals Inc
$ 24.59
-0.57%
24 Feb - close price
- Market Cap 4,183,866,000 USD
- Current Price $ 24.59
- High / Low $ 25.19 / 24.49
- Stock P/E 15.95
- Book Value 5.42
- EPS 1.55
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.35 %
- 52 Week High 28.35
- 52 Week Low 13.40
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Analyst Target Price
$31.53
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-02 | 2023-05-08 | 2023-02-27 |
| Reported EPS | 0.42 | 0.16 | 0.11 | 0.86 | 0.2 | 0.2 | 0.1 | 0.28 | -0.4 | 0.01 | -0.27 | -0.26 |
| Estimated EPS | 0.14 | 0.14 | 0.05 | 0.219 | 0.14 | 0.18 | 0.05 | 0.3 | -0.43 | -0.08 | -0.21 | -0.24 |
| Surprise | 0.28 | 0.02 | 0.06 | 0.641 | 0.06 | 0.02 | 0.05 | -0.02 | 0.03 | 0.09 | -0.06 | -0.02 |
| Surprise Percentage | 200% | 14.2857% | 120% | 292.6941% | 42.8571% | 11.1111% | 100% | -6.6667% | 6.9767% | 112.5% | -28.5714% | -8.3333% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACAD
2026-02-23 21:53:39
Mizuho upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to Outperform from Neutral, raising its price target to $35.00 due to the underappreciated potential of remlifanserin (ACP-204) in its Phase 2 RADIANT trial for Alzheimer's disease psychosis. The firm believes the market is overlooking the new drug's potential, especially given the planned higher dosage and appropriate powering for the new trial, which should enhance efficacy compared to previous trials. This upgrade comes despite recent setbacks for Acadia's other treatment, trofinetide, in Europe.
2026-02-23 21:20:12
ACADIA Pharmaceuticals is transitioning from a reliance on its single product, Nuplazid, towards a more diversified neurology and rare disease pipeline. Recent analyst commentary highlights this shift, though concerns remain regarding DAYBUE uptake, regulatory hurdles, and potential U.S. drug pricing reforms impacting Nuplazid's Medicare exposure. Despite these challenges, the company projects significant revenue and earnings growth by 2028, with a fair value estimate suggesting a 30% upside from its current price.
2026-02-23 13:06:00
Mizuho has upgraded ACADIA Pharmaceuticals (ACAD) stock from Neutral to Outperform and increased its price target from $29 to $35. This positive revision comes despite recent news regarding Acadia's Rett Syndrome medication being less likely to receive EU approval, which has led to other analysts trimming their price targets. ACADIA Pharmaceuticals is focused on developing and commercializing medicines for central nervous system disorders and rare diseases.
2026-02-23 12:00:34
Over the last three months, 10 analysts have evaluated ACADIA Pharmaceuticals (NASDAQ: ACAD), leading to an average price target of $32.7, a 7.57% increase from the previous average. The company shows strong financials with positive revenue growth, exceptional net margin, and high returns on equity and assets, while maintaining a balanced debt-to-equity ratio. Analysts have recently updated their ratings and price targets, reflecting varied sentiments but an overall upward trend in expectations for the biopharmaceutical company.
2026-02-23 01:12:00
This article analyzes Acadia Pharmaceuticals Inc. (ACAD) from a tactical trading perspective, highlighting a positive near-term sentiment within a long-term strong context, despite a mid-term weak bias. It outlines an exceptional risk-reward setup targeting a 14.0% gain with minimal risk, and presents three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The analysis emphasizes the critical price action for tactical trading and offers institutional-grade signals for various risk profiles.
2026-02-21 11:52:25
Jupiter Asset Management Ltd. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by 25.2% in the third quarter of 2025, selling over 160,000 shares. Other institutional investors showed mixed activity, with some increasing and others decreasing their holdings. The biopharmaceutical company is trading at $23.99, with a consensus "Moderate Buy" rating from Wall Street analysts and an average target price of $30.95.
